Chronic hand eczema, which can develop from chemicals and cleansers that people use frequently for work, now has its first FDA-approved treatment. The new LEO Pharma drug, Anzupgo, is a topical cream designed to block four signaling proteins that drive inflammation.
Leaders in pharma’s AI age won’t be remembered for moving the fastest, but for earning and keeping trust along the way. Privacy will determine which companies pull ahead and which fall behind, making it one of the industry’s biggest tests.
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
Creating a specialty pharmacy in a space-challenged hospital campus can seem like a daunting task, particularly in a crowded metropolitan or suburban area. Here are some creative solutions to solve for this barrier.
We’d like to know what we can do to deliver more for our readers.
Roche’s astegolimab met the main goal of one pivotal COPD study but failed another, mirroring the mixed results recently posted by a Regeneron Pharmaceuticals COPD drug candidate that goes after the same target. Biologics are a new treatment option for COPD following approvals of antibodies from Sanofi and GSK.
As scientists and researchers figure out the right balance of GLP-1 to glucagon ratio and a better drug delivery method, we are beginning to turn the page for the many individuals suffering from obesity.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Sarepta’s Elevidys will remain on the market with a black box warning. But this gene therapy for Duchenne muscular dystrophy still faces commercial headwinds and analysts say the company has work to do to win over patients and investors.
The Phase 3 results in China are encouraging for Kailera Therapeutics, which holds rights to the molecule in the rest of the world. The startup is preparing a global clinical development program for this drug, a once-weekly injectable GLP-1 and GIP receptor agonist.
This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
Capricor Therapeutics said the FDA asked for more data supporting the efficacy of Deramiocel, the biotech’s off-the-shelf cell therapy for treating the heart complications of Duchenne muscular dystrophy. Those data could come from an ongoing Phase 3 study expected to yield preliminary results soon.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a heavily pretreated patient population and a favorable safety profile.
AI is no panacea, but it can have a role in turning artisanal, trial-and-error drug development into a rapid, cost-effective, data-driven process.
Novartis malaria drug Coartem has expanded its approval to include babies. The combination drug, originally formulated as a tablet, has a new dose strength and formulation designed for treating newborns and young infants who develop malarial infections.
Novartis’s Cosentyx failed to beat a placebo in a Phase 3 clinical trial in giant cell arteritis. The antibody drug was being developed as an alternative to Roche and AbbVie drugs whose approved uses include treating this autoimmune disorder affecting blood vessels.
Success with agentic AI won’t come from racing to adopt the flashiest tools. It will come from strategic alignment, understanding where AI can create real value, mitigating risk through thoughtful implementation, and ensuring transparency and oversight at every step.